Itraclar 200 Capsule contains Itraconazole 200 mg, a broad-spectrum triazole antifungal agent indicated for the treatment of various fungal infections. Itraconazole exerts its antifungal effect by inhibiting the cytochrome P450-dependent enzyme lanosterol 14-α-demethylase, which is essential for the conversion of lanosterol to ergosterol, a key component of fungal cell membranes. Disruption of ergosterol synthesis results in increased membrane permeability and ultimately fungal cell death. Itraclar 200 is effective against a wide range of pathogenic fungi, including dermatophytes, yeasts such as Candida species, and molds like Aspergillus species. It is commonly prescribed for conditions such as onychomycosis, blastomycosis, histoplasmosis, aspergillosis, and other systemic and superficial mycoses. The capsule formulation ensures adequate bioavailability and systemic distribution. Dosage and duration of therapy should be individualized based on the type and severity of infection, patient response, and tolerability. Caution is advised in patients with hepatic impairment or congestive heart failure, and potential drug interactions should be carefully monitored due to itraconazole’s effect on cytochrome P450 enzymes. Adverse effects may include gastrointestinal disturbances, headache, and elevated liver enzymes. Regular monitoring of liver function tests is recommended during prolonged therapy.